Ipilimumab相关论文
Phase 1/2 study of nivolumab with or without ipilimumab for treatment of recurrent SCLC:CA209-032 (N
Objective: Patients (pts) with SCLC respond to initial platinum (PLT) based chemotherapy (CT), but rapidly progress.Comb......
Clinical response, progression-free survival(PFS), and safety in patients (pts) with advanced melano
Objective: Combined blockade of T-cell checkpoints by NIVO and IPI demonstrated a high objective response rate (ORR), pr......
...
免疫疗法是一种快速发展的治疗自身免疫病和癌症的方法。细胞毒性T淋巴细胞抗原4(cytotoxic T lymphocyte antigen 4，CTLA-4)是适应......
Background: Ipilimumab is a fully human immunoglobulin G1 monoclonal antibody that increases antitumor T-cell respon......
Nivolumab（商品名Opdivo），一种由百时美施贵宝公司研制的单克隆抗体，是程序性死亡受体（PD-1）阻断剂。至2015年10月，FDA已批准其单用或联用......
你以前也许未听说过:ipilimumab:与:nivolumab:两个药,不过这2种药物未来将会有效治疗皮肤癌。研究表明,上述两种药物联合使用能够......
美国FDA于2011年3月25日批准百时美施贵宝(BMS)公司产品ipilimumab(商品名:Yervoy)用于治疗转移性黑色素瘤。本品也于近日获得欧洲......
美国FDA于2011年3月25日批准百时美施贵宝(BMS)公司产品ipilimumab(商品名:Yervoy)用于治疗转移性黑色素瘤。本品也于近日获得欧洲......
目的：系统评价易普利姆玛的有效性和安全性。方法：计算机检索PubMed,Cochrane Library,Embase,中国知网、万方和维普数据库。由2位研......
1 文献来源rn研究一:Hellmann MD,Ciuleanu TE,Pluzanski A,et al. Nivolumab plus Ipilimumab in lung cancer with a high tumor......
Ipilimumab associated colitis: An Ipi Colitis case series at Med Star Georgetown University Hospital
Although ipilimumab has been shown to improve survival in patients with metastatic melanoma and cause regression of meta......
Ipilimumab associated colitis: An Ipi Colitis case series at Med Star Georgetown University Hospital
Although ipilimumab has been shown to improve survival in patients with metastatic melanoma and cause regression of meta......
Healthcare Resource Utilization and Associated Costs in Patients with Advanced Melanoma Receiving Fi
Background: To describe healthcare costs, excluding ipilimumab drug costs, in patients with advanced melanoma receiving ......
Administration of ipilimumab,a cytotoxic T-lymphocyte associated antigen-4-blocking monoclonal antibody,leads to enhance......
BACKGROUND A variety of immune-modulating drugs are becoming increasingly used for various cancers.Despite increasing in......
With the recent development and clinical application, immune checkpoint inhibitors (ICIs) intervention is being increasi......
Background: Following approval of ipilimumab, this observational cohort study (CA184-332) was initiated to describe pati......
恶性黑素瘤是一种恶性程度极高、对放化疗不敏感、病死率很高的肿瘤，目前有较多研究对其各种治疗方法进行探索。最近恶性黑素瘤治疗......
Vedolizumab in combined immune checkpoint therapy-induced infliximab-refractory colitis in a patient
BACKGROUND Dual checkpoint inhibition improves response rates in treatment naive patients with metastatic melanoma compa......
Immunotherapy is any treatment aimed at boosting or enhancing the immune system.It includes a wide range of options,from......
第一部分Ipilimumab的药代动力学研究目的:本文旨在研究抗体药物ipilimumab在临床前小鼠模型C57BL/6J小鼠,CTLA4人源化小鼠以及CTL......
目的:本研究的主要目的在于评估Ipilimumab联合Nivolumab对比Nivolumab单药治疗肿瘤患者发生免疫相关不良事件(irAEs)的风险。患者......
目的:免疫检查点抑制剂(Immune checkpoint inhibitors,ICIs)是近年来肿瘤治疗领域的一个热点。ICIs治疗显著延长了恶性肿瘤患者的......
...
1文献来源研究一:Hellmann MD,Ciuleanu TE,Pluzanski A,et al.Nivolumab plus Ipilimumab in lung cancer with a high tumor mut......
美国FDA于2011年3月25日批准百时美施贵宝（BMS）公司产品ipilimumab（商品名：Yervoy）用于治疗转移性黑色素瘤。本品也于近日获得欧洲人用......
期刊
回 回 产卜爹仇贱回——回 日E回。”。回祖 一回“。回干 肉果幻中 N_。NH lP7-ewwe--一”＄ MN。W;- __._——————》 砧叫]们......
Ipilimumab(MDX-010),是一种新型的CTLA-4(cytotoxic T-lymphocyte antigen-4,细胞毒性T淋巴细胞相关抗原4)抑制剂,由百时美-施贵......
期刊
BACKGROUND Colitis is one of the immune-related side effects of immunotherapy.Usually,such type of side effect was repor......
Ipilimumab是一种新型的抗CTLA-4(细胞毒性T淋巴细胞相关抗原4)的全人源单克隆抗体。阻断CTLA-4的免疫效应可以打破免疫系统对自身......
ipilimumab是溶解性T细胞相关抗原(CTLA-4)的单克隆抗体。其作用机制为中和CTLA-4的免疫抑制作用,从而激发机体的抗肿瘤免疫反应。......
细胞毒性T淋巴细胞相关蛋白4(CTLA-4)为共刺激分子,表达于活化的CD4+和CD8+T细胞,与其配体B7分子结合后产生抑制性信号。CTLA-4阻......
期刊
背景与目的：以检查点（checkpiont）为靶点的免疫治疗在实体瘤治疗领域有巨大的应用价值,引发了免疫靶向药物的研究热潮。一项研究结果......
期刊
